跳至主要内容
临床试验/NCT00913081
NCT00913081已完成4 期

Advancing Niacin by Inhibiting FLUSHing: (ANTI-FLUSH)

University of Pennsylvania4 个研究点 分布在 1 个国家目标入组 17 人开始时间: 2009年2月最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
入组人数
17
试验地点
4
主要终点
Whether Quercetin Dose-dependently Reduces Laser Doppler Flux Index Primary Peak Following Immediate-release Niacin

研究概览

简要总结

Niacin, or vitamin B3, is known to improve cholesterol disorders and is the most effective drug to raise HDL, or the "good cholesterol". The use of niacin has been limited because of a peculiar adverse effect referred to as "flushing', which consists of redness, warmth, tingling and burning. A recent animal study suggests that flavonoids may prevent flushing due to niacin better than drugs like aspirin. The ANTI-FLUSH study is being done to assess whether a presently available dietary supplement known as quercetin, which is a flavonoid, can reduce the flushing that occurs with niacin. We will also assess whether using quercetin to prevent flushing from niacin, can improve how niacin lowers cholesterol.

详细描述

This study involves people between 21 and 75 years. It will be conducted over a period of 8 weeks, with 4 visits, each separated by 2 weeks. The duration of each visit is 9-10 hours. We will test a different dose of quercetin in each visit.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Supportive Care
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
21 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Men and women from the age of 21 to 75, inclusive - 16 subjects, 8 men, 8 women.
  • Ability to understand and agree to informed consent.
  • Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures.

排除标准

  • Contra-indications or known intolerance to the study medications.
  • History of congestive heart failure, carcinoid, rosacea, renal failure (GFR<60 ml/min/m2).
  • Active liver disease.
  • Active diabetes (defined as any history of type 1 diabetes, or history of type 2 diabetes plus one or more of the following: fasting glucose>= 126mg/dL at screening or use of anti-diabetic medications within 12 months, or glucose>200mg/dL 2 hours after a 75 g oral glucose challenge within 12 months.
  • History of major surgery within the past 6 weeks, or anticipated major surgery during the course of the study, or any history of organ transplant.
  • History of drug abuse within the past 3 years, or regular alcohol use of greater than 14 drinks per week.
  • Women who are pregnant, plan to conceive or lactate.
  • Peri-menopausal women or women currently experiencing flushing.
  • Currently taking vasoactive medications, anti-hypertensives, anti-histamines, Selective Serotonin Re-uptake Inhibitors (SSRIs), NSAIDS, oral steroids, leukotriene inhibitors, supplemental quercetin and > 50mg niacin.

结局指标

主要结局

Whether Quercetin Dose-dependently Reduces Laser Doppler Flux Index Primary Peak Following Immediate-release Niacin

时间窗: 8 hour period

Laser Doppler flowmetry at the malar eminence measures blood flow quantitatively as red blood cell flux. Flux index is the fold-change in flux over baseline. Flux index primary peak is the maximum flux index between 0-4 hours after niacin.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验

Advancing Niacin by Inhibiting Flushing (ANTI-FLUSH) | 临床试验